DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study.
This study examined the possible association between the polymorphism in the dopamine receptor DRD4 gene and response to risperidone among 24 Israeli Jewish adolescent inpatients with first-episode schizophrenia. Response was categorically determined by a change of >40% on the Brief Psychiatric Rating Scale (BPRS). No significant association was found between the DRD4 genotype and clinical response, although carriers of <7 repeat alleles demonstrated higher response rate (10/20 vs. 0/4, P=0.11). Studies in larger groups of adolescent schizophrenia patients are warranted to clarify the possible association between DRD4 exon III repeat alleles and the response to risperidone.
Zalsman
Gil
G
Adolescent Inpatient Department, Geha Mental Health Center, Rabin Medical Center, Petach Tikva 49100, Israel. zalsman@post.tau.ac.il
Frisch
Amos
A
Lev-Ran
Shaul
S
Martin
Andrés
A
Michaelovsky
Elena
E
Bensason
Daniela
D
Gothelf
Doron
D
Nahshoni
Eitan
E
Tyano
Samuel
S
Weizman
Abraham
A
D000293:Adolescent; D000483:Alleles; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004247:DNA / Q000235:genetics; D005091:Exons / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D006801:Humans; D007557:Israel; D008297:Male; D010597:Pharmacogenetics; D010865:Pilot Projects; D011110:Polymorphism, Genetic / Q000235:genetics*; D011569:Psychiatric Status Rating Scales; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D050638:Receptors, Dopamine D4; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics*
D014150:Antipsychotic Agents; C493599:DRD4 protein, human; D017448:Receptors, Dopamine D2; D050638:Receptors, Dopamine D4; D004247:DNA; D018967:Risperidone